에 대한 최신 뉴스 Bloom Energy (NYSE:BE) 주식

BLOOM ENERGY CORP- A

Bloom Energy

Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and internationally.

Elon Musk's SpaceX And T-Mobile Go Live With Starlink-Powered Satellite-To-Cell Service: Here's How Much It Will Cost

News

Markets

Tech

TSLA

일론 머스크가 이끄는 스페이스X가 수십억 달러 규모의 새로운 연방 계약을 체결하기 직전인 것으로 알려졌다고 보도되었다. 스페이스X는 최초로 인간을 화성으로 수송하기 위한 연방 계약을 추진 중이다. 이는 머스크가 NASA가 화성에 집중하도록 촉구하는 것과 일치하는 맥락이다.

일론 머스크의 스페이스X, 트럼프 행정부와 수십억 달러 연방 계약 추진 중:  NYT 보도

Long,Beach,,Ca,,Usa,-,July,10,,2022:,Rocket,Labs

Mid Cap

Movers

Trading Ideas

IONQ

NPWR

RKLB

이 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 블룸 에너지(NYSE:BE)의 주식은 여러 애널리스트들이 목표 주가를 상향 조정한 후, 지난 주 55.44% 상승했다.

로켓랩과 헛 8 마이닝은 지난주 최고 성과를 보여준 7개 중형주 중 일부 (11월 11일-15일)

Solar,Panels,Wind,Turbines,Installed,As,Renewable,Energy,Sources,For

Analyst Color

Government

Large Cap

Downgrades

Price Target

Analyst Ratings

General

FSLR

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

SEDG

TPIC

최근 미국 대통령 선거 결과, 특히 공화당의 압승은 도널드 트럼프 대통령 당선인의 지도하에 재생 에너지의 미래에 대한 의문을 제기했다. 모건 스탠리의 보고서는 다양한 정책 시나리오에 따른 재생 에너지의 경제적 영향을 평가하고, 이것이 수익성에 미치는 영향을 분석한다.

트럼프의 당선, 경제적 도전으로 인해 재생 에너지 주식의 전망이 암울: 모건 스탠리

Bloom Energy Corporation Class A Common Stock

Bloom Energy Corp

Bold Eagle Acquisition Corp. - Class A Ordinary Shares

Bold Eagle Acquisition Corp

Bold Eagle Acquisition Corp. - Right

Beam Therapeutics Inc

BEAM - United States Dollar

BEAR Coin - United States Dollar

HeartBeam Inc

bebe stores Inc

BCE Inc

Beacon Roofing Supply, Inc. - Common Stock

Beacon Roofing Supply Inc

BlackRock ETF Trust Future Climate & Sustainable Economy ETF

Bechtle AG

BEC WRLD PCL ADR by Bec World Public Co., Ltd.

BEC World PCL

Bright Scholar Education Holdings Limited American Depositary Shares, each representing four Class A Ordinary Share

Bright Scholar Education Holdings Ltd

AdvisorShares Hotel ETF

BALD EAGLE ENERGY INC by Bald Eagle Energy, Inc.

Beam Global

BETTER ENVIRONMENT CNCPT by Better Environment Concepts, Inc.

Mobile Infrastructure Corporation Common Stock

Mobile Infrastructure Corp

The Beehive ETF

Honeytree U.S. Equity ETF

BLACKSTAR ENTERPRISE GRP by BlackStar Enterprise Group, Inc.

Blackstar Enterprise Group Inc

Collaborative Investment Series Trust Rareview 2x Bull Cryptocurrency & Precious Metals ETF

BIOCENTRIC ENGY HLDGS INC by Biocentric Energy Holdings, Inc.

Biocentric Energy Holdings

BeiGene Ltd

BEIJING NORTH STAR CORP by Beijing North Star Corp.

Beijing North Star Co Ltd

NV Bekaert SA

KE Holdings Inc American Depositary Shares (each representing three Class A Ordinary Shares)

KE Holdings Inc

Bella Protocol

Batero Gold Corp

Bel Fuse Inc

Bellevue Gold Ltd

BELMONT RESOURCES INC by Belmont Resources, Inc.

Belmont Resources Inc

BELL ROSE CAPITAL INC by Bell Rose Capital Inc.

Bell Rose Capital Inc

iShares Long-Term U.S. Equity Active ETF

Belt Finance

BEMIL Coin

iShares Trust iShares J.P. Morgan Broad USD Emerging Markets Bond ETF

BANGKOK EXPWY METRO NVDR by Bangkok Expwy & Metro Pub Co Ltd

Franklin Resources Inc

BENS CREEK GROUP PLC by BENS CREEK GROUP PLC

Bens Creek Group PLC

Beneficient

BARITO RENEWABLES ENERGY by BARITO RENEWABLES ENERGY TBK

BIO-EN HOLDINGS CORP by Bio-En Holdings Corp.

Bio-En Holdings Corp

Horizon Funds Horizon Landmark ETF

Benz Mining Corp

BEO Bancorp OR

Beyond Oil Ltd

Brookfield Renewable Partners L.P. Limited Partnership Units

Brookfield Renewable Partners LP

Brookfield Renewable Corporation Brookfield Renewable Corporation Class A Subordinate Voting Shares

Brookfield Renewable Corp

Brookfield BRP Holdings (Canada) Inc. 4.625% Perpetual Subordinated Notes

Brookfield BRP Holdings (Canada) Inc. 4.875% Perpetual Subordinated Notes

Brookfield BRP Holdings (Canada) Inc. 7.250% Perpetual Subordinated Notes

BEPRO Network

Beach Energy Ltd

Brookfield Renewable Partners L.P. 5.25% Class A Preferred Limited Partnership Units, Series 17

BLUE EARTH RES INC by Blue Earth Resources, Inc.

Blue Earth Resources Inc

ROCKLAND RESOURCES LTD by Rockland Resources Ltd.

Berry Global Group Inc

MicroSectors FANG & Innovation -3x Inverse Leveraged ETN

Besra Gold Inc

BELSHIPS CO LTD ORD by Belships Co., Ltd.

Belships ASA

BE SMCNDCTR INDUS S/ADR by BE Semiconductor Industries N.V.

BE Semiconductor Industries NV

BIMERGEN ENERGY CORP by Bimergen Energy Corporation

Bimergen Energy Corp

BEST Inc SPONSORED ADR NEW 2023

Bitpanda - United States Dollar

BE SMCNDCTR INDUS N V by BE Semiconductor Industries N.V.

Beta Finance

ProShares Bitcoin & Ether Equal Weight ETF

ProShares Bitcoin & Ether Market Cap Weight ETF

Better Home & Finance Holding Company - Class A Common Stock

Better Home & Finance Holding Co

BETTERLIFE PHARMA INC by BETTERLIFE PHARMA INC.

BetterLife Pharma Inc

Better Home & Finance Holding Company - Warrant

BIT BROTHER LIMITED A by Bit Brother Limited

Bit Brother Ltd

BetU

BETTWORK INDUSTRIES INC by Bettwork Industries Inc.

Bettwork Industries Inc

Roundhill Sports Betting & iGaming ETF

SCIENCE TO CONSUMERS INC by Science to Consumers, Inc.

Science to Consumers Inc

DIVERSIFIED ROYALTY CORP by Diversified Royalty Corp.

Diversified Royalty Corp

BEE VECTORING TECH ORD by Bee Vectoring Technologies International Inc.

Bee Vectoring Technologies International Inc

BEWHERE HLDGS INC by BeWhere Holdings Inc.

BeWhere Holdings Inc

Earnings

RCAT

Red Cat Holdings 2024 Transition Period EPS $(0.57); Revenue $4.9M

Guidance

GDEV

GDEV Q4 Revenue $98M Down From $109M QoQ.

<p>TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle.</p>


ASND

Ascendis Submits New Drug Application To FDA For TransCon CNP For Treatment Of Children With Achondroplasia.

<p>In the last three months, 8 analysts have published ratings on The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $132.5, along with a high estimate of $140.00 and a low estimate of $125.00. This current average reflects an increase of 1.44% from the previous average price target of $130.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451282_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive The Hartford Insurance Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$126.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to The Hartford Insurance Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of The Hartford Insurance Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of The Hartford Insurance Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of The Hartford Insurance Gr's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HIG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on The Hartford Insurance Gr analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind The Hartford Insurance Gr</h2>
<p>The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments including Business Insurance, Personal Insurance, Property &amp; Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.</p>
<h3>The Hartford Insurance Gr: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> The Hartford Insurance Gr's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>7.54%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> The Hartford Insurance Gr's net margin is impressive, surpassing industry averages. With a net margin of <strong>12.47%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The Hartford Insurance Gr's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.17%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The Hartford Insurance Gr's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.05%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.27</strong>, The Hartford Insurance Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing The Hartford Insurance Gr: Insights From 8 Financial Analysts

<p>During the last three months, 5 analysts shared their evaluations of Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $370.0, along with a high estimate of $400.00 and a low estimate of $350.00. This upward trend is evident, with the current average reflecting a 2.42% increase from the previous average price target of $361.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451268_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Snap-on among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macgregor</td>
<td>Longbow Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$400.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Snap-on. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Snap-on compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Snap-on's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Snap-on's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Snap-on analyst ratings.</strong></a></p>
<h2>Discovering Snap-on: A Closer Look</h2>
<p>Snap-on manufactures premium tools and software for repair professionals. Hand tools are sold through a franchisee-operated mobile van network that serve auto technicians who purchase tools at their own expense. A unique element of its business model is that franchisees bear significant risk, as they must invest in the mobile van, inventory, and software. At the same time, franchisees extend personal credit directly to technicians on an individual tool basis. Snap-on currently operates three segments: repair systems and information, commercial and industrial, and tools. Its finance arm provides financing to franchisees to run their operations, which includes offering loans and leases for mobile vans.</p>
<h3>Snap-on: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Snap-on's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>0.18%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Snap-on's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>21.53%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Snap-on's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>4.75%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>3.26%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.24</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Snap-on: Insights From 5 Analyst Reviews

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Home Depot</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HD, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Home Depot.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 28% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $119,477, and 10 are calls, for a total amount of $1,564,142.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $415.0 for Home Depot, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Home Depot options trades today is 484.31 with a total volume of 1,809.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Home Depot's big money trades within a strike price range of $200.0 to $415.0 over the last 30 days.</p>
<h3>Home Depot Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451267_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$31.1</td>
<td>$29.6</td>
<td>$31.1</td>
<td>$380.00</td>
<td>$622.0K</td>
<td>51</td>
<td align="right">200</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.9</td>
<td>$410.00</td>
<td>$361.9K</td>
<td>1.7K</td>
<td align="right">937</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$25.25</td>
<td>$25.1</td>
<td>$25.25</td>
<td>$350.00</td>
<td>$154.0K</td>
<td>186</td>
<td align="right">65</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$3.65</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$365.00</td>
<td>$123.6K</td>
<td>316</td>
<td align="right">390</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$167.25</td>
<td>$163.3</td>
<td>$165.18</td>
<td>$200.00</td>
<td>$82.5K</td>
<td>12</td>
<td align="right">11</td>
</tr>
</tbody>
</table>
</p>
<h3>About Home Depot</h3>
<p>Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The additions of the Company Store brought textiles to the lineup, and the 2024 tie-up with SRS will help grow professional demand in roofing, pool and landscaping projects.</p>
<p>Following our analysis of the options activities associated with Home Depot, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Home Depot</h3>
<ul>
<li>With a volume of 2,316,777, the price of HD is up 2.71% at $367.85. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 43 days.</li>
</ul>
<h3>What The Experts Say On Home Depot</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $418.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Home Depot, targeting a price of $418. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Home Depot with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

What the Options Market Tells Us About Home Depot

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Accenture</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ACN, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Accenture.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 35% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $382,190, and 5 are calls, for a total amount of $183,546.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $350.0 for Accenture over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Accenture's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Accenture's whale trades within a strike price range from $300.0 to $350.0 in the last 30 days. </p>
<h3>Accenture Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451262_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$17.6</td>
<td>$17.4</td>
<td>$17.5</td>
<td>$300.00</td>
<td>$61.2K</td>
<td align="right">358</td>
<td align="right">101</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$17.6</td>
<td>$17.3</td>
<td>$17.6</td>
<td>$300.00</td>
<td>$52.8K</td>
<td align="right">358</td>
<td align="right">52</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$28.3</td>
<td>$25.7</td>
<td>$27.9</td>
<td>$340.00</td>
<td>$50.2K</td>
<td align="right">7</td>
<td align="right">18</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$9.9</td>
<td>$9.6</td>
<td>$9.9</td>
<td>$310.00</td>
<td>$48.5K</td>
<td align="right">149</td>
<td align="right">97</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/04/25</td>
<td>$1.45</td>
<td>$1.1</td>
<td>$1.4</td>
<td>$315.00</td>
<td>$46.7K</td>
<td align="right">59</td>
<td align="right">912</td>
</tr>
</tbody>
</table>
</p>
<h3>About Accenture</h3>
<p>Accenture is a leading global IT services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.</p>
<p>Following our analysis of the options activities associated with Accenture, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Accenture</h3>
<ul>
<li>Trading volume stands at 2,992,244, with ACN's price up by 2.75%, positioned at $312.71.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 81 days.</li>
</ul>
<h3>What Analysts Are Saying About Accenture</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $383.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Accenture, which currently sits at a price target of $372.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on Accenture, maintaining a target price of $390.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Accenture, maintaining a target price of $396.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Accenture, targeting a price of $387.<br />
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Accenture with a target price of $370. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Accenture with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


What the Options Market Tells Us About Accenture

<p>In the last three months, 13 analysts have published ratings on Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $19.4, a high estimate of $22.00, and a low estimate of $16.00. Marking an increase of 4.75%, the current average surpasses the previous average price target of $18.52. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451258_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Invesco by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Etienne Ricard</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.75</td>
<td>$19.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$19.50</td>
<td>$17.00</td>
</tr>
<tr>
<td>Stephen Biggar</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$17.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$19.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Invesco. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Invesco compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Invesco's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Invesco's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IVZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Invesco analyst ratings.</strong></a></p>
<h2>About Invesco</h2>
<p>Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of October 2024, the firm had $1.792 trillion in assets under management spread among its equity (58% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (10%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's us retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 29% of its AUM sourced from Europe, Africa, and the Middle East (14%) and Asia (15%).</p>
<h3>Key Indicators: Invesco's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Invesco's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>12.71%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Invesco's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>13.14%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.97%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Invesco's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.77%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Invesco's debt-to-equity ratio is below the industry average at <strong>0.72</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Invesco: Insights From 13 Analyst Reviews

<p>Deep-pocketed investors have adopted a bullish approach towards Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MSFT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 248 extraordinary options activities for Microsoft. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 43% leaning bullish and 39% bearish. Among these notable options, 129 are puts, totaling $9,995,941, and 119 are calls, amounting to $8,253,185.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $115.0 to $530.0 for Microsoft over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Microsoft's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Microsoft's whale activity within a strike price range from $115.0 to $530.0 in the last 30 days. </p>
<h3>Microsoft Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451257_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSFT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.65</td>
<td>$14.55</td>
<td>$14.65</td>
<td>$365.00</td>
<td>$366.2K</td>
<td>3.5K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$0.8</td>
<td>$0.75</td>
<td>$0.8</td>
<td>$390.00</td>
<td>$271.7K</td>
<td>3.3K</td>
<td>12.7K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$19.45</td>
<td>$19.4</td>
<td>$19.4</td>
<td>$375.00</td>
<td>$193.9K</td>
<td>2.1K</td>
<td>118</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$19.4</td>
<td>$19.25</td>
<td>$19.35</td>
<td>$375.00</td>
<td>$193.5K</td>
<td>2.1K</td>
<td>418</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$19.45</td>
<td>$19.35</td>
<td>$19.35</td>
<td>$375.00</td>
<td>$193.5K</td>
<td>2.1K</td>
<td>318</td>
</tr>
</tbody>
</table>
</p>
<h3>About Microsoft</h3>
<p>Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).</p>
<p>In light of the recent options history for Microsoft, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Microsoft's Current Market Status</h3>
<ul>
<li>With a trading volume of 18,083,669, the price of MSFT is down by -1.14%, reaching $374.49.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 24 days from now.</li>
</ul>
<h3>Expert Opinions on Microsoft</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $518.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Microsoft, which currently sits at a price target of $475.<br />
&#x2A; An analyst from Tigress Financial persists with their Buy rating on Microsoft, maintaining a target price of $595.<br />
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $550.<br />
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Microsoft, targeting a price of $500.<br />
&#x2A; Reflecting concerns, an analyst from Scotiabank lowers its rating to Sector Outperform with a new price target of $470.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Microsoft options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


MSFT

This Is What Whales Are Betting On Microsoft

<p>7 analysts have expressed a variety of opinions on Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $116.86, a high estimate of $150.00, and a low estimate of $78.00. This current average reflects an increase of 33.88% from the previous average price target of $87.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451250_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Corcept Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$78.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Corcept Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corcept Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Corcept Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Corcept Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CORT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Corcept Therapeutics analyst ratings.</strong></a></p>
<h2>Get to Know Corcept Therapeutics Better</h2>
<p>Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.</p>
<h3>Key Indicators: Corcept Therapeutics's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Corcept Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>34.33%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>16.71%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.61%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Corcept Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>3.74%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.01</strong>, Corcept Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CORT

Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings)

<p>6 analysts have shared their evaluations of Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $142.33, along with a high estimate of $163.00 and a low estimate of $130.00. A decline of 7.88% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451242_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Qualys by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$130.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$146.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$135.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Michael Walkley</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Qualys. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Qualys compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Qualys's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Qualys's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/QLYS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Qualys analyst ratings.</strong></a></p>
<h2>Get to Know Qualys Better</h2>
<p>Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.</p>
<h3>Key Indicators: Qualys's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Qualys displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.11%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Qualys's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>27.62%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Qualys's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>9.49%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Qualys's ROA excels beyond industry benchmarks, reaching <strong>4.67%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Qualys's debt-to-equity ratio is below the industry average. With a ratio of <b>0.1</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QLYS

The Analyst Verdict: Qualys In The Eyes Of 6 Experts

YOSH

Yoshiharu Regains Nasdaq Compliance

<p>In the last three months, 33 analysts have published ratings on Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">22</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">7</td>
<td align="right">11</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $121.91, a high estimate of $160.00, and a low estimate of $72.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.88%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451226_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Trade Desk by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$101.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$101.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$83.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Matthew Condon</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$115.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$122.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$130.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$103.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$135.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Vikram Kesavabhotla</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$90.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Alex Markgraff</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Wolfe Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Trade Desk. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Trade Desk compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Trade Desk's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Trade Desk's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TTD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Trade Desk analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Trade Desk</h2>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on devices like computers, smartphones, and connected TVs. It uses data in an iterative manner to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry, and it generates revenue from fees based on a percentage of what its clients spend on advertising.</p>
<h3>Unraveling the Financial Story of Trade Desk</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Trade Desk's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>22.32%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> Trade Desk's net margin is impressive, surpassing industry averages. With a net margin of <strong>24.59%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Trade Desk's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>6.54%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Trade Desk's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.14%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Trade Desk's debt-to-equity ratio is below the industry average at <strong>0.11</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Trade Desk: 33 Analysts Share Their Views

<p>In the current session, the stock is trading at $86.77, after a <strong>1.07%</strong> spike. Over the past month, <strong>Cava Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>)</strong> stock increased by <strong>0.16%</strong>, and in the past year, by <strong>31.38%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1743451224_0.png" alt="Past Year Chart" /></p>

<h3>Cava Group P/E Compared to Competitors</h3>
<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. </p>
<p>Cava Group has a lower P/E than the aggregate P/E of <strong>85.38</strong> of the Hotels, Restaurants &amp; Leisure industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1743451224_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

CAVA

Price Over Earnings Overview: Cava Group

<p>argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) has outperformed the market over the past 5 years by 17.3% on an annualized basis producing an average annual return of 34.95%. Currently, argenx has a market capitalization of $35.80 billion. </p>
<p><strong>Buying $1000 In ARGX:</strong> If an investor had bought $1000 of ARGX stock 5 years ago, it would be worth <strong>$4,435.15</strong> today based on a price of $589.15 for ARGX at the time of writing.</p>
<h3>argenx's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451210_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ARGX

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years

WIIM

The Goodyear Tire & Rubber Company shares are trading higher after Deutsche Bank upgraded the stock from Hold to Buy and announced a $13 price target.

<p><strong>Bluebird Bio Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares are trading higher Monday after the company received an unsolicited takeover <a href="https://www.benzinga.com/25/03/44564776/gene-therapy-focused-bluebird-bio-receives-rival-takeover-offer-stock-jumps">offer from Ayrmid Ltd</a>.</p>
<p><strong>What To Know:</strong> The offer includes an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of net sales milestones.</p>
<p>The bid comes after Bluebird had already agreed in February to be acquired and taken private by Carlyle and SK Capital Partners for $3 per share in cash, with the same $6.84 contingent value right. </p>
<p>Bluebird said it previously reviewed strategic alternatives and even engaged in discussions with Ayrmid, but Ayrmid did not submit a proposal at that time. The company's board is now reviewing the new offer with legal and financial advisors. Investors appear to be reacting to the possibility of a higher takeover price.</p>
<p>Bluebird Bio shares are also getting a boost from Barclays on Monday after the analyst firm maintained an <a href="https://www.benzinga.com/analyst-stock-ratings">Overweight rating</a> and set a price target of $8.</p>
<p><strong>Blue Price Action:</strong> BlueBird Bio shares were up 24.1% at $5.06 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-1024x544.png" alt="" class="wp-image-849883" style="width:388px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57.png 1494w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/econ-s/25/03/44567966/stocks-fall-sp-500-eyes-worst-month-in-almost-two-years-oil-rallies-whats-driving-markets-monday">Stocks Fall, S&amp;P 500 Eyes Worst Month In Almost Two Years, Oil Rallies: What&#8217;s Driving Markets Monday?</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


BLUE

BlueBird Shares Are Up Today: What's Going On?

Domino's Pizza shares are trading higher after TD Securities reiterated its buy rating and maintained a $490 price target on the stock.

<hr class="wp-block-separator has-alpha-channel-opacity" />
<p>Something I love about&nbsp;<a href="https://substack.com/redirect/a33e217c-3912-4c2f-8f9e-91aa704311e3?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">Barry Ritholtz's writing</a>&nbsp;is how he often surprises you with unexpected insights.</p>
<p>Sure, he advances well-known — but still underappreciated — wisdom like how&nbsp;<a href="https://substack.com/redirect/b527f577-a1fb-4953-99e9-cd156d26a4bd?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">index fund investing</a>&nbsp;is hard to beat and why&nbsp;<a href="https://substack.com/redirect/bd663486-e3a2-4ec0-a249-1e62906a66d6?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">making short-term market forecasts is futile</a>.</p>
<p>But he offers much more than that.</p>
<p>Take this excerpt on psychology from his new book, "<a href="https://substack.com/redirect/2235c538-5abb-496b-bb99-5bb8c6756d36?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">How Not To Invest</a>," which he shared in a recent piece for&nbsp;<a href="https://substack.com/redirect/af8bee2f-570d-4fcd-a829-2829bdb6c503?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">Bloomberg</a>:</p>
<p><strong><em>Trick Your Lizard Brain</em></strong></p>
<p><em>Nobel laureate Paul Samuelson once said, "Investing should be more like watching paint dry or watching grass grow. If you want excitement, take $800 and go to Las Vegas." While the dopamine hit that comes from a risky stock bet paying off may be enjoyable, passive management is the better option for most investors looking to grow long-term wealth.</em></p>
<p><em>The catch is that you must take steps to protect yourself from, well, yourself. To do so, set up a "mad-money account" — or a cowboy account, as it's sometimes called. Add less than 5% of your liquid capital, so maybe $5,000 if you're liquid enough to have $100,000 as a safety net. Now you can indulge your inner hedge fund manager without jeopardizing anything too material.</em></p>
<p><em>If it works out, you're more likely to let those winners run because it's for fun and not your real money. If it's a debacle, appreciate the terrific lesson that should remind you that this is not your forte.</em></p>
<p>In his book, Barry shares a little more on what he personally does:</p>
<p><em>In my cowboy account, using 2% of my liquid net worth, I play the dumbest game possible: Market timing with out-of-the-money stock option calls…</em></p>
<p>He discusses specific trades he's made. I'll let you buy the book if you really want the details.</p>
<p>Here's his bottom line.</p>
<p><em>Regardless of the results, it allows my inner junkie to leave my main portfolio alone. That is the true value of the cowboy account — my real money remains unmolested by me and my big dumb lizard brain.</em></p>
<p>Like most of us, Barry is not a machine. He is a human with a brain. And when your brain is mismanaged, it can be your worst enemy.</p>
<p>The idea of having a "cowboy account" is not without its issues. Some of you might say it could be a slippery slope towards costlier risk taking. This advice certainly isn't for everybody. But let's also not pretend like living in denial of your instincts and biases isn't risky either.</p>
<p>As TKer subscribers know, my investing mostly consists of&nbsp;<a href="https://substack.com/redirect/e28d3a82-b2cd-452d-881f-d49dc3af9f7d?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">buying and holding passively managed index funds</a>. But while I may have&nbsp;<a href="https://substack.com/redirect/69499d0e-028f-4e14-80f6-5c62a33bd29b?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">lost my taste for picking stocks</a>&nbsp;and timing the market a long time ago, I haven't lost my appetite for risk.</p>
<p>Personally, I've taken Samuelson's advice much more literally. Occasionally, I like to play craps live in a casino. That's the game where you often hear crowds of people cheer loudly as they engage in the mania of a "hot" table. I won't get into too much detail, but it's a game where I can lose enough that it's memorably painful but not so much that it's material to my finances. Importantly, it satiates my risk appetite, and it gives me renewed appreciation for my financial plan at relatively low cost.</p>
<p>In some ways, investing is like dieting: For many people, attempting to cut out junk food entirely just doesn't work.</p>
<p>If you want to learn more about how real people can better navigate the treacherous world of investing, buy Barry's book. He's got real world solutions for your real world challenges.</p>
<p><em>For more info, head to</em>&nbsp;<strong><em><a href="https://substack.com/redirect/2235c538-5abb-496b-bb99-5bb8c6756d36?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">HowNotToInvestBook.com</a></em></strong>&nbsp;»</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td></td>
<td><img loading="lazy" decoding="async" width="550" height="609" src="blob:https://contributor.benzinga.com/6ab83874-4823-43db-a6cf-f0bc4b23db56" /><a href="https://substack.com/redirect/7dcc4b4e-bc26-45cf-8706-e80464a39081?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener"></a></td>
<td></td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p>(Source:&nbsp;<a href="https://substack.com/redirect/2235c538-5abb-496b-bb99-5bb8c6756d36?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">How Not To Invest</a>)</p>
<p><strong>&nbsp;Sam Ro mention!</strong></p>
<p>I was shocked and humbled to learn that Barry mentioned me in "<a href="https://substack.com/redirect/2235c538-5abb-496b-bb99-5bb8c6756d36?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">How NOT To Invest</a>." I've been reading his blogs since before the financial crisis. He's had a huge impact on how I think and write about markets.</p>
<p>If you like TKer, then you'll love Barry's writing. Catch up on his views by&nbsp;<a href="https://substack.com/redirect/2235c538-5abb-496b-bb99-5bb8c6756d36?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">reading his book</a>!</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td></td>
<td><img loading="lazy" decoding="async" width="550" height="410" src="blob:https://contributor.benzinga.com/c52a613c-0da2-46f1-9062-0366e83cc0b6" /><a href="https://substack.com/redirect/5b122bfa-6cc5-4129-bd35-103393fb06a0?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener"></a></td>
<td></td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p>From "How NOT To Invest"</p>


Comments

Bloom Energy

뉴스

에 대한 최신 뉴스 Bloom Energy (NYSE:BE) 주식

월요일, 3월 24, 2025

일요일, 11월 17, 2024

토요일, 11월 16, 2024

금요일, 5월 10, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌